Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Digestive and Liver Disease

Volumn 42, Issue 12, 2010, Pages 902-907

  Svicher, Valentina ^a   Alteri, Claudia ^a   Gori, Caterina ^b   Salpini, Romina ^a   Marcuccilli, Fabbio ^a   Bertoli, Ada ^a   Longo, Roberta ^c   Bernassola, Martina ^c   Gallinaro, Valentina ^d   Romano, Sara ^c   Visca, Michela ^c   Ursitti, Antonella ^c   Feasi, Marcello ^e   Micheli, Valeria ^f   Angelico, Mario ^a   Cassola, Giovanni ^e   Parruti, Giustino ^g   Gubertini, Guido ^f   De Sanctis, Giuseppe Maria ^d   Ceccherini Silberstein, Francesca ^a   Cappiello, Giuseppina ^c   Spanò, Alberto ^c   Perno, Carlo Federico ^a   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c SANDRO PERTINI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Drug resistance; HBV; Low viral replication

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; VIRAL LOAD; VIREMIA;

EID: 78650286696     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.04.017     Document Type: Article

References (16)

1. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49:S174-S184.
2. Suzuki F., Tsubota A., Arase Y. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003, 46:182-189.
3. Baldick C.J., Tenney D.J., Mazzucco C.E., et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008, 47:1473-1482.
4. Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
5. Lampertico P., Viganò M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42:1414-1449.
6. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000, 32:847-851.
7. Papatheodoridis G.V., Dimou E., Laras A., et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002, 36:219-226.
8. Svicher V., Gori C., Trignetti M., et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009, 50:461-470.
9. Freshwater D.A., Dudley T., Cane P., et al. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008, 85:1105-1111.
10. Holomán J., Glasa J. EASL clinical practice guidelines. J Hepatol 2009, 51:821-822.
11. Yatsuji H., Noguchi C., Hiraga N., et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006, 50:3867-3874.
12. Warner N., Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of virological breakthrough. Hepatology 2008, 48:88-98.
13. Lai M.W., Huang S.F., Hsu C.W., et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 2009, 14:249-261.
14. Han Y., Huang L.H., Miao Liu C., et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. J Gastroenterol Hepatol 2009, 24:1417-1423.
15. Rodriguez C., Chevaliez S., Pallier C., et al. Ultra-deep sequencing analysis demonstrates pre-existence of HBV resistance substitution at baseline in patients who subsequently develop clinical resistance. CROI 2010, [Abst N 170lb].
16. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008, 61:766-768.